ellen zwijnenburg

Mrs. ellen zwijnenburg

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
EZellen zwijnenburg
ellen zwijnenburg
SLSatish F.K. Lubeek
Satish F.K. Lubeek
JWJohanna E.M. Werner
Johanna E.M. Werner
AAAvital L. Amir
Avital L. Amir
WWWillem L.J. Weijs
Willem L.J. Weijs
Johannes KaandersJohannes Kaanders
Johannes Kaanders
Merkel cell carcinoma (MCC) is a rare neuroendocrine tumor of the skin mainly seen in the elderly. Its incidence is rising due to ageing of the population, increased sun exposure, and the use of immunosuppressive medication. Additionally, with the availability of specific immunohistochemical markers, MCC is easier to recognize. Typically, these tumors are rapidly progressive and behave aggressively, emphasizing the need for early detection and prompt diagnostic work-up and start of treatment. In this review, the tumor biology and immunology, current diagnostic and treatment modalities, as well as new and combined therapies for MCC, are discussed. MCC is a very immunogenic tumor which offers good prospects for immunotherapy. Given its rarity, the aggressiveness, and the frail patient population it concerns, MCC should be managed in close collaboration with an experienced multidisciplinary team.

5 October 2025 in Radiotherapy and Oncology
Verified
Journal Article
Open access
SBSven van Den Bosch
Sven van Den Bosch
MCMaurice C. Cox
Maurice C. Cox
PDPatricia A.H. Doornaert
Patricia A.H. Doornaert
FHFrank Hoebers
Frank Hoebers
BKBas Kreike
Bas Kreike
JKJohannes H.A.M. Kaanders
Johannes H.A.M. Kaanders
The multicenter, randomized UPGRADE-RT trial (NCT02442375) evaluated the safety and clinical benefit of elective neck radiotherapy with reduced versus standard dose in head and neck squamous cell carcinoma (SCC). This is a secondary analysis of acute toxicity. Three hundred patients with cT2-4 N0-2 M0 SCC of the oropharynx, larynx or hypopharynx received definitive accelerated radiotherapy alone (34 fractions of 2 Gy in 5.5 weeks). Dose for elective neck irradiation was randomly assigned (ratio 2:1 to dose reduction, 43 Gy versus control, 50 Gy). Radiation induced acute toxicity was scored according to the CTC v2.0 until 90 days after start of radiotherapy. The analysis included 295 evaluable patients (dose reduction, 196 and control, 99). Dysphagia grade ≥ 3 (requiring tube feeding) occurred significantly less in the dose reduction group compared to controls (RR, 0.56, [95 % CI, 0.32 to 0.98], p = 0.046). A mean dose ≥ 45 Gy to the pharyngeal mucosal epithelium was associated with increased rates of mucositis grade ≥ 3 (RR, 1.41, [95 % CI, 1.17 to 1.70], p < 0.001) and dysphagia grade ≥ 3 requiring tube feeding (RR, 3.61, [95 % CI, 1.72 to 7.57], p < 0.001). Less patients in the dose reduction group had a pharyngeal mucosal epithelium mean dose ≥ 45 Gy (RR, 0.80, [95 % CI, 0.65 to 0.99], p = 0.041). Reduced elective dose resulted in significantly more patients with a pharyngeal mucosal epithelium mean dose below 45 Gy. This was associated with a reduced rate of grade ≥ 3 pharyngeal mucositis and a lower rate of acute dysphagia grade ≥ 3 (requiring tube feeding).

23 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
IRIrene van Rijn-Dekker
Irene van Rijn-Dekker
Arjen Van der SchaafArjen Van der Schaaf
Arjen Van der Schaaf
SNSanne W. Nienhuis
Sanne W. Nienhuis
AAAntoinette Arents-Huls
Antoinette Arents-Huls
RGRachel B. Ger
Rachel B. Ger
RSRoel J.H.M. Steenbakkers
Roel J.H.M. Steenbakkers
Background/Objectives: Studies have shown that dose to the parotid gland stem cell rich (SCR) regions should be reduced to lower the risk of xerostomia after radiotherapy (RT). This study aimed to assess whether stem cell sparing (SCS)-RT can be adopted in routine clinical practice. Methods: Multiple planning studies were performed to compare SCS-RT with standard (ST)-RT using 30 head and neck cancer patients. Shifts in mean dose to the SCR regions (Dmean,SCR) and other organs at risk and their estimated impact on normal tissue complication probability (NTCP) for side-effects were compared using Wilcoxon signed-rank test. A multicenter study was performed (eight institutions, three patients) to test the generalizability of SCS-RT using the Friedman test. Results: Using photons, Dmean,SCR was reduced with median 4.1/3.5 Gy for ipsilateral/contralateral (p < 0.001). The largest reductions were when the SCR regions overlapped less with target volumes. Subsequently, NTCPs for xerostomia decreased (p < 0.001). Using protons, Dmean,SCR was also reduced (2.2/1.9 Gy for ipsilateral/contralateral, p < 0.002). Nevertheless, SCS-RT did not further decrease NTCPs for xerostomia (p > 0.17). Target coverage and prevention of other side-effects were not compromised. However, increased mean oral cavity dose was observed in some patients. Lastly, in the multicenter study Dmean,SCR could be reduced by slightly adjusting the standard optimization. Contralateral Dmean,SCR reductions differed between centers (p = 0.01), which was attributed to differences in ST-RT plans. Conclusions: Stem cell sparing radiotherapy can be clinically introduced by making small adjustments to the optimization strategy and can reduce the risk of xerostomia.

2 November 2025 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
AAAbrahim Al-Mamgani
Abrahim Al-Mamgani
GVGerda Verduijn
Gerda Verduijn
EZellen zwijnenburg
ellen zwijnenburg
WSWillem H. Schreuder
Willem H. Schreuder
ASAniel Sewnaik
Aniel Sewnaik
MRMischa de Ridder
Mischa de Ridder